BRPI0513475A - derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc - Google Patents

derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc

Info

Publication number
BRPI0513475A
BRPI0513475A BRPI0513475-7A BRPI0513475A BRPI0513475A BR PI0513475 A BRPI0513475 A BR PI0513475A BR PI0513475 A BRPI0513475 A BR PI0513475A BR PI0513475 A BRPI0513475 A BR PI0513475A
Authority
BR
Brazil
Prior art keywords
piperidine
disorders
cinolin
quinazolin
treatment
Prior art date
Application number
BRPI0513475-7A
Other languages
English (en)
Inventor
Thomas Allen Chappie
John Michael Humphrey
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0513475A publication Critical patent/BRPI0513475A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

DERIVADOS QUINAZOLIN-4 - IL-PIPERIDINA E CINOLIN-4- IL-PIPERIDINA COMO INIBIDORES DE PDE-10 NO TRATANENTO DE DISTúRBIOS DO SNC A invenção é pertinente a novos derivados quinazolina e isoquinolina piperidi1-substituídos de fórmula (I), que se prestam como eficazes inibidores de fosfodiesterase (PDE). A invenção também se refere a compostos que são inibidores seletivos de PDE-10. A invenção refere-se ainda, a intermediários para a preparação de tais compostos; composições farmacêuticas compreendendo tais compostos e ao uso desses compostos nos métodos de tratamento de alguns distúrbios do sistema nervoso central (SNC) ou de outros distúrbios.
BRPI0513475-7A 2004-07-23 2005-07-11 derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc BRPI0513475A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59094304P 2004-07-23 2004-07-23
PCT/IB2005/002177 WO2006011040A1 (en) 2004-07-23 2005-07-11 Quinazolin-4-yl- piperidine and cinnolin-4-yl- piperidine derivatives as pde10 inhibitors for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
BRPI0513475A true BRPI0513475A (pt) 2008-05-06

Family

ID=34972555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513475-7A BRPI0513475A (pt) 2004-07-23 2005-07-11 derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc

Country Status (25)

Country Link
US (1) US20060019975A1 (pt)
EP (1) EP1773805A1 (pt)
JP (1) JP2008507500A (pt)
CN (1) CN1989124A (pt)
AP (1) AP2007003891A0 (pt)
AR (1) AR050433A1 (pt)
AU (1) AU2005266080A1 (pt)
BR (1) BRPI0513475A (pt)
CA (1) CA2574685A1 (pt)
CR (1) CR8861A (pt)
EA (1) EA200700097A1 (pt)
EC (1) ECSP077193A (pt)
GT (1) GT200500198A (pt)
IL (1) IL180205A0 (pt)
MA (1) MA28746B1 (pt)
MX (1) MX2007000878A (pt)
NL (1) NL1029596C2 (pt)
NO (1) NO20065948L (pt)
PE (1) PE20060570A1 (pt)
SV (1) SV2006002175A (pt)
TN (1) TNSN07021A1 (pt)
TW (1) TW200616641A (pt)
UY (1) UY29028A1 (pt)
WO (1) WO2006011040A1 (pt)
ZA (1) ZA200700223B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481969T1 (de) * 2004-10-01 2010-10-15 Merck Sharp & Dohme Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
JP2008531709A (ja) * 2005-03-01 2008-08-14 ワイス シンノリン化合物および肝臓ｘ受容体調節物質としてのそれらの使用
US20100222353A1 (en) * 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
CA2643963A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007098214A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
JPWO2007119361A1 (ja) * 2006-03-17 2009-08-27 三菱瓦斯化学株式会社 キナゾリン−４−オン誘導体の製造方法
PT2057153E (pt) * 2006-07-10 2012-11-14 Lundbeck & Co As H Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1903038A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
WO2009025839A2 (en) * 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US7858620B2 (en) * 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW200918519A (en) * 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
ES2397934T3 (es) 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
WO2011143366A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
AU2011253143A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
DK3126354T3 (da) * 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
IN148482B (pt) * 1977-06-03 1981-03-07 Pfizer
JPS60120872A (ja) * 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
EP0638567A4 (en) * 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
US5614627A (en) * 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AU2003255528B2 (en) * 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives

Also Published As

Publication number Publication date
UY29028A1 (es) 2006-02-24
US20060019975A1 (en) 2006-01-26
NL1029596A1 (nl) 2006-01-24
EP1773805A1 (en) 2007-04-18
ECSP077193A (es) 2007-02-28
EA200700097A1 (ru) 2007-06-29
IL180205A0 (en) 2007-07-04
NO20065948L (no) 2007-01-23
CR8861A (es) 2007-03-02
AP2007003891A0 (en) 2007-02-28
TNSN07021A1 (fr) 2008-06-02
PE20060570A1 (es) 2006-07-14
ZA200700223B (en) 2008-08-27
MA28746B1 (fr) 2007-07-02
CN1989124A (zh) 2007-06-27
SV2006002175A (es) 2006-02-15
NL1029596C2 (nl) 2006-09-06
JP2008507500A (ja) 2008-03-13
AU2005266080A1 (en) 2006-02-02
AR050433A1 (es) 2006-10-25
TW200616641A (en) 2006-06-01
WO2006011040A1 (en) 2006-02-02
CA2574685A1 (en) 2006-02-02
MX2007000878A (es) 2007-03-12
GT200500198A (es) 2006-03-02

Similar Documents

Publication Publication Date Title
BRPI0513475A (pt) derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc
UY28750A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
CU23780B7 (es) Compuestos de quinolina heteroaromaticos y su uso como inhibidores de pde10
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
YU51703A (sh) Derivati benzimidazola i piridilimidazola kao veznici za gaba receptore
UY30080A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
BRPI0814529B8 (pt) derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
IL173802A0 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
BRPI0517955A (pt) indolizinas substituìdas e derivados como agentes de snc
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
UA85701C2 (ru) Способ получения ингибиторов триптазы
DE602006016430D1 (de) Phosphodiesteraseinhibitoren auf azolbasis
DOP2005000139A (es) Nuevos derivados piperidilo do quinazolina e isoquinolina
DOP2006000004A (es) Compuestos de quinolina heteroaromaticos.
TW200716602A (en) Novel compounds
TH80544B (th) สารประกอบเฮเทอโรแอโรแมทิค ควิโนลีน
TW200738646A (en) Novel compounds

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]